Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA ‐REG OUTCOME trial

ConclusionsIn patients with type 2 diabetes mellitus and established CV disease, those with AF at baseline had higher rates of adverse HF outcomes than those without AF. Irrespective of the presence of AF, empagliflozin reduced HF ‐related and renal events. The absolute number of prevented events is higher in patients with AF than without AF. Patients with diabetes, CV disease and AF may especially benefit from use of empagliflozin.

Source: European Journal of Heart Failure - December 8, 2019 Category: Cardiology Authors: Michael B öhm, Jonathan Slawik, Martina Brueckmann, Michaela Mattheus, Jyothis T. George, Anne Pernille Ofstad, Silvio E. Inzucchi, David Fitchett, Stefan D. Anker, Nikolaus Marx, Christoph Wanner, Bernard Zinman, Subodh Verma Tags: Research Article Source Type: research